Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study

Heart failure (HF) occurs in 1–2% of the world’s population [1]. Despite standard therapy, such as renin–angiotensin–aldosterone system inhibitors, beta blockers, or diuretics, there is a requirement for an unmet need [2]. In particular, HF is a major comorbidity in patients with type 2 diabetes mellitus (T2DM), which is caused by diverse pathogenic factors such as the cardiotoxic tetrad of coronary artery disease, diabetic cardiomyopathy, or hypertension. HF reduces quality of life, results in hospitalization, and contributes to a large socioeconomic loss [1, 3].

Some studies have indicated that HF is associated with oral hypoglycemic agents, which has attracted worldwide attention. Rosiglitazone has been withdrawn from the market because it was reported to cause HF. Saxagliptin has been reported to be associate with HF, which has caused global controversy [4, 5]. Unlike these two drugs, empagliflozin reduced hospitalization for heart failure (hHF) by 35% in a randomized controlled trial (RCT) called the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) [6], and this tendency was the same when only Asian patients were analyzed [7]. In another RCT, the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program, canagliflozin reduced hHF, suggesting the protective effect of sodium glucose co-transporter 2 inhibitors (SGLT-2i) as a class effect on HF [8]. Although there is no RCT, multinational observational studies have shown that dapagliflozin is also protective against HF [9]. In the EMPA-REG OUTCOME trial, only patients with established cardiovascular disease (CVD) were included. About 70% of the participants in the CANVAS program had established CVD, and the remaining participants were patients with two or more CVD risks. Thus, after the results of these studies were published, concerns about the effect of SGLT-2i on HF in patients without established CVD were raised.

An early separation of survival curves for hHF was observed in the EMPA-REG OUTCOME trial and CANVAS Program, although no differences were observed in myocardial infarction or cerebral infarction [6, 8]. This finding suggests that the HF protective effect of SGLT-2i could be derived through a non-glycemic anti-atherosclerotic mechanism, such as a diuretic effect, a hemo-concentration effect, a ketone body-producing effect, or a uric acid lowering effect. However, to the best of our knowledge, no observational study has been conducted to determine how soon SGLT-2i-treated patients show a lower incidence of hHF.

We compared HF risk of SGLT-2i with dipeptidyl peptidase-4 inhibitors (DPP-4i) as an active comparator because both drugs are similarly used as a second-line treatment and have a low risk of hypoglycemia and weight gain, as well as a potent glucose-lowering effect. Although there is still debate and no consensus, DPP-4i has been shown not to elevate the risk of heart failure in many studies [10‐13].

We aimed to evaluate the HF protective effect of SGLT-2i compared with DPP-4i. In addition, we sought to estimate whether the HF protective effect of SGLT-2i differs depending on the underlying CVD and the prescription period.

Our results show that SGLT-2i use reduced hHF compared with DPP-4i use. Patients with underlying CVD were associated with a reduced risk of hHF from 30 days after initiating the SGLT-2i to the third year, but patients without underlying CVD showed a significantly lower risk of HF in the third year.

In our study, SGLT-2i use reduced hHF by 36% compared with DPP-4i use, which is consistent with the results of the EMPA-REG OUTCOME trial, the CANVAS Program, and three observational studies [6, 8, 9, 14, 15]. In the EMPA-REG OUTCOME trial, empagliflozin reduced hHF by 35% (95% CI, 0.50–0.85; p = 0.002) vs. placebo [6]. In addition, in the CANVAS Program, which included data integrated from the CANVAS and CANVAS-R trials, canagliflozin showed a 33% reduction in hHF (95% CI, 0.52–0.87) vs. placebo [8]. The finding that hHF began to be separated widely within 3 months and was maintained for 3 years in two previous RCTs has brought worldwide interest [2, 16‐18]. However, no statistical analysis has been performed to determine how soon patients benefit for hHF after using SGLT-2i; thus, there is a need to analyze the impact of hHF by dividing the duration of SGLT-2i use. Therefore, we analyzed hHF according to the duration of SGLT-2i use and showed that hHF was significantly lower in SGLT-2i new users vs. DPP-4i new users beginning 30 days after initiating SGLT-2i. This finding suggests that patients with T2DM and established CVD may benefit from HF management at the initiation of SGLT-2i use.

Several mechanisms have been proposed to explain the early HF protective effect of SGLT-2i. First, it induces a negative caloric balance and reduces hemoglobin A1c and body weight by causing glycosuria [16]. However, our results show that hHF decreased beginning 30 days after initiating the SGLT-2i, which was similar to previous RCTs [6, 8]. The protective effect of HF is achievable within a short time although improvements in the glycemic and lipid profiles were modest at 3 months in those RCTs; thus, it likely occurs via a non-glycemic mechanism. Second, SGLT-2i improves hemodynamics through natriuresis, which was suggested as a pivotal mechanism to improve HF in the early phase of drug initiation in some studies [2, 19‐21]. Sodium glucose co-transporter 2 resorbs about 5% of the sodium under normal conditions and this capacity increases under a chronic hyperglycemic condition [2, 16, 22‐24]. Thus, SGLT-2i decrease plasma volume which consequently reduces preload and ventricular filling pressure, and lowers blood pressure, which causes a reduction in afterload and improves subendocardial blood flow. Third, a shift in fuel energetics has been suggested as a protective mechanism for HF and has been called the “thrifty substrate” hypothesis [17, 25]. This hypothesis proposes that SGLT-2i induce ketogenesis, including β-hydroxybutyrate, in patients with T2DM [25, 26]. β-hydroxybutyrate is freely taken up by the heart and used as an energy-efficient “superfuel” to improve cardiac metabolism, such as oxygen consumption, at the mitochondrial level and also increase cardiac hydraulic efficiency in animal HF model [17, 18, 27, 28]. Finally, SGLT-2i may exert a cardioprotective effect by lowering uric acid level. Plasma uric acid level is associated with congestive HF and CVD [29‐31]. SGLT-2i use causes secretion of uric acid via the GLUT9 transporter, resulting in a 10–15% reduction in plasma uric acid level [32, 33].

Previous RCTs included only patients with underlying CVD or patients at high risk for CVD; thus, there is a concern whether SGLT-2i have similar benefits in patients with T2DM who do not have established CVD. One observational study showed that SGLT-2i use on T2DM patients without underlying DM complication showed lower HR without statistical significance (adjusted HR = 0.83; 95% CI = 0.54–1.27; p = 0.40) [34]. However, in our study, hHF decreased significantly in the third year among patients without underlying CVD. The difference between our study result and that of Gautam et al. was probably due to the fact that we performed subgroup analysis according to the presence of underlying cardiovascular disease, whereas their analysis was based on the presence of any DM complications (any microvascular or macrovascular complications). Furthermore, they enrolled just 5000 patients, which was smaller than our study. To our knowledge, no observational study has analyzed the HF protective effect of SGLT-2i use with CVD stratification. This is the first study to estimate the HF protective effect among patients without established CVD.

In our study, SGLT-2i use reduced hHF compared with DPP-4i use beginning 30 days after initiating the drug among patients with underlying CVD, which was far earlier than patients without CVD. This result is in agreement with the results of a previous EMPA-REG sub study showing that SGLT-2i use was associated with a lower risk of hospitalization for HF from 360 to 1440 days after the drug initiation [35]. Also, although there was no statistical analysis to determine whether HF risk varies with follow-up period in the CANVAS program, early separation in the K–M curve of hHF after drug initiation was more prominent in the EMPA-REG OUTCOME trial, where all participants had previous history of CVD, compared to the CANVAS program that enrolled 34.4% participants who had no previous history of CVD [6, 8]. Our finding and the results from previous studies suggests that the effectiveness of HF protective mechanism with SGLT-2i use could be different depending on the patient’s underlying CVD. As our results and results of previous RCTs show, patients with T2DM and established CVD could benefit from SGLT-2i use beginning when the drug is initiated. Among the several mechanisms described above, such as a hemodynamic effect, and shift in fuel energetics, SGLT-2i could be more beneficial to patients with established CVD. One study showed that SGLT-2i decreased systolic blood pressure and increased diuresis among T2DM patients in just 48 h after initiation [20], and that this effect lasts relatively longer [22]. Also, after just a single dose of SGLT-2i, T2DM patients showed increased ketogenesis, which could directly benefit hemodynamics in heart failure patients [17, 25, 28]. Maybe these hemodynamic or metabolic changes could protect T2DM patients with established CVD immediately after SGLT-2i use, but later in patients without established CVD. However, our study did not analyze laboratory or echocardiographic results to determine the underlying mechanisms. Therefore, further evaluation is needed to identify the HF protective mechanism in patients with or without underlying CVD.

Several strengths of the present study should be mentioned. First, to our knowledge, this is the first study to estimate HF risk with CVD stratification and show that the HF protective effect of SGLT-2i can vary depending on whether patients have established CVD or not. Second, our results are the first to show that SGLT-2i have significant effects on HF beginning just 30 days after initiating the drug. This could be a meaningful finding and confirm the conjectures of previous studies. Third, this study was a nationwide population-based cohort study including over 50,000 new users of SGLT-2i. Finally, our study compared the SGLT-2i class, which is of great interest, with DPP-4i, one of the most widely used oral hypoglycemic agents in the world. By comparing these two drug classes and strictly adjusting all other oral hypoglycemic agents associated with hHF, physicians who consider prescribing both drugs will be directly helped in clinical situations with real world data.

Our research had some limitations. First, we used claims data, which do not contain information about measurements such as laboratory or echocardiography results, New York Heart Association Functional Classification of heart failure, socio-economic status, or diabetes duration; consequently, residual confounding factors probably existed. To compensate for this limitation, we performed propensity score matching with 55 variables including several complications of diabetes and HF medications. However, propensity score matching is not a remedy for all confounding factors, so our results should be interpreted with caution. In addition, we only adjusted prescribed medication before, but not after, the index date and, thus, there are still residual confounding factors. Second, we could not analyze mortality after use of SGLT-2i because the HIRA database does not contain mortality data. As previous RCTs and observational studies have already shown that SGLT-2i use is associated with improved mortality, our study could be more meaningful as it focused on the effect of SGLT-2i on HF in greater detail. Third, we could not analyze the HF risk of SGLT-2i according to the presence of underlying HF because there were only two thousand patients with underlying heart failure, which was too small for analysis.

Our results suggest that SGLT-2i reduced hHF compared with DPP-4i. A HF protective effect of SGLT-2i vs. DPP-4i was shown 30 days after initiating the SGLT-2i among patients with established CVD, but this effect appeared later in patients without established CVD.